A detailed history of Pro Share Advisors LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 17,963 shares of NTLA stock, worth $288,485. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,963
Previous 23,235 22.69%
Holding current value
$288,485
Previous $639,000 37.09%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$20.02 - $27.22 $105,545 - $143,503
-5,272 Reduced 22.69%
17,963 $402,000
Q1 2024

May 08, 2024

BUY
$23.82 - $32.8 $58,740 - $80,884
2,466 Added 11.87%
23,235 $639,000
Q4 2023

Feb 14, 2024

BUY
$23.16 - $32.34 $77,030 - $107,562
3,326 Added 19.07%
20,769 $633,000
Q3 2023

Nov 13, 2023

BUY
$31.62 - $45.78 $1,549 - $2,243
49 Added 0.28%
17,443 $551,000
Q2 2023

Aug 10, 2023

BUY
$34.58 - $46.03 $38,418 - $51,139
1,111 Added 6.82%
17,394 $709,000
Q1 2023

May 11, 2023

SELL
$33.3 - $44.82 $81,651 - $109,898
-2,452 Reduced 13.09%
16,283 $606,000
Q4 2022

Feb 02, 2023

BUY
$33.21 - $62.69 $93,618 - $176,723
2,819 Added 17.71%
18,735 $653,000
Q3 2022

Nov 04, 2022

BUY
$53.92 - $71.7 $21,082 - $28,034
391 Added 2.52%
15,916 $890,000
Q2 2022

Aug 01, 2022

SELL
$38.49 - $76.21 $264,618 - $523,943
-6,875 Reduced 30.69%
15,525 $804,000
Q1 2022

May 10, 2022

SELL
$58.27 - $118.99 $294,380 - $601,137
-5,052 Reduced 18.4%
22,400 $1.63 Million
Q4 2021

Feb 08, 2022

BUY
$100.76 - $138.36 $131,189 - $180,144
1,302 Added 4.98%
27,452 $3.25 Million
Q3 2021

Nov 12, 2021

SELL
$132.37 - $176.78 $353,427 - $472,002
-2,670 Reduced 9.26%
26,150 $3.51 Million
Q2 2021

Aug 13, 2021

BUY
$60.88 - $161.91 $293,441 - $780,406
4,820 Added 20.08%
28,820 $4.67 Million
Q1 2021

May 14, 2021

BUY
$46.59 - $83.68 $176,110 - $316,310
3,780 Added 18.69%
24,000 $1.93 Million
Q4 2020

Feb 09, 2021

BUY
$18.83 - $63.53 $87,013 - $293,572
4,621 Added 29.62%
20,220 $1.1 Million
Q3 2020

Nov 13, 2020

BUY
$17.47 - $24.93 $25,017 - $35,699
1,432 Added 10.11%
15,599 $310,000
Q2 2020

Aug 03, 2020

BUY
$11.14 - $22.87 $157,820 - $323,999
14,167 New
14,167 $298,000
Q1 2020

May 15, 2020

SELL
$9.44 - $15.58 $149,265 - $246,350
-15,812 Closed
0 $0
Q4 2019

Feb 12, 2020

SELL
$10.43 - $17.67 $19,003 - $32,194
-1,822 Reduced 10.33%
15,812 $232,000
Q3 2019

Nov 12, 2019

BUY
$13.07 - $18.51 $10,181 - $14,419
779 Added 4.62%
17,634 $235,000
Q2 2019

Aug 13, 2019

SELL
$13.88 - $18.41 $29,439 - $39,047
-2,121 Reduced 11.18%
16,855 $276,000
Q1 2019

May 15, 2019

BUY
$12.79 - $17.62 $9,784 - $13,479
765 Added 4.2%
18,976 $324,000
Q4 2018

Feb 14, 2019

SELL
$11.39 - $27.13 $39,500 - $94,086
-3,468 Reduced 16.0%
18,211 $249,000
Q3 2018

Nov 14, 2018

SELL
$25.78 - $32.6 $20,727 - $26,210
-804 Reduced 3.58%
21,679 $620,000
Q2 2018

Aug 13, 2018

BUY
$20.02 - $30.79 $15,595 - $23,985
779 Added 3.59%
22,483 $615,000
Q1 2018

May 14, 2018

SELL
$19.43 - $34.95 $69,559 - $125,121
-3,580 Reduced 14.16%
21,704 $458,000
Q4 2017

Feb 14, 2018

BUY
$17.39 - $31.12 $69,020 - $123,515
3,969 Added 18.62%
25,284 $486,000
Q3 2017

Nov 13, 2017

BUY
$15.16 - $25.75 $23,786 - $40,401
1,569 Added 7.95%
21,315 $530,000
Q2 2017

Aug 11, 2017

BUY
N/A
19,746
19,746 $316,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.22B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.